David Amsellem
Stock Analyst at Piper Sandler
(4.83)
# 88
Out of 5,134 analysts
161
Total ratings
66.67%
Success rate
23.97%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $232.86 | +28.40% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $195.62 | -9.52% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $15.74 | -23.76% | 8 | Jan 28, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $62 → $66 | $60.35 | +9.36% | 2 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $183.30 | +21.66% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $8.73 | +106.19% | 1 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $30 → $40 | $34.41 | +16.25% | 11 | Dec 22, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $167.98 | +30.37% | 15 | Dec 10, 2025 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.55 | +153.52% | 1 | Nov 25, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $373.36 | +2.05% | 6 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $3.88 | +106.19% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $6.91 | +15.77% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $15.19 | -14.42% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $127.76 | +40.11% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $32.90 | +36.78% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $51.64 | +25.88% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $28.45 | -12.13% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $39.63 | +205.32% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.28 | +147.25% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $46.10 | -19.74% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $78.90 | -13.81% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.99 | -49.92% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.74 | +84.70% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $4.78 | +339.33% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $36.92 | +13.76% | 3 | Oct 16, 2023 |
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $232.86
Upside: +28.40%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $195.62
Upside: -9.52%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $15.74
Upside: -23.76%
Bristol-Myers Squibb Company
Jan 28, 2026
Maintains: Overweight
Price Target: $62 → $66
Current: $60.35
Upside: +9.36%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $183.30
Upside: +21.66%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $8.73
Upside: +106.19%
Teva Pharmaceutical Industries
Dec 22, 2025
Maintains: Overweight
Price Target: $30 → $40
Current: $34.41
Upside: +16.25%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $167.98
Upside: +30.37%
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.55
Upside: +153.52%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $373.36
Upside: +2.05%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $3.88
Upside: +106.19%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.91
Upside: +15.77%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $15.19
Upside: -14.42%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $127.76
Upside: +40.11%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $32.90
Upside: +36.78%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $51.64
Upside: +25.88%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $28.45
Upside: -12.13%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $39.63
Upside: +205.32%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.28
Upside: +147.25%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $46.10
Upside: -19.74%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $78.90
Upside: -13.81%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.99
Upside: -49.92%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.74
Upside: +84.70%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $4.78
Upside: +339.33%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $36.92
Upside: +13.76%